Trial Profile

Region-specific Adipose Tissues and Liver Changes Associated With Semaglutide Treatment in Chronic Kidney Disease Patients

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics
Acronyms ADIPOLIVE

Most Recent Events

17 Nov 2025 Planned number of patients changed from 62 to 52.
17 Nov 2025 Planned primary completion date changed from 15 Nov 2027 to 15 Dec 2027.
17 Nov 2025 Planned initiation date changed from 15 Sep 2025 to 15 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com